NewsResearch
CheckMate 025: What the Kidney Cancer Trial Found
CheckMate 025 compared nivolumab with everolimus in advanced kidney cancer. People lived longer on the immune drug even though their scans showed no delay in tumour growth — a mismatch that changed how such trials are read.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
A survival gain the scans did not show
Most cancer trials work on a simple logic. A drug slows the tumour down, you see that on a scan, and people live longer as a result. CheckMate 025 broke that chain. People on the immune drug lived about five months longer. Their scans looked no better than the other group's.
That result forced oncologists to stop treating scan-based measures as a stand-in for survival when immune drugs are involved.
Who was in it, and what they had already tried
821 people with advanced clear-cell kidney cancer took part. All of them had already had one or two courses of anti-angiogenic treatment — drugs that attack the blood supply a tumour builds for itself — and their cancer had kept going.
They were split evenly. Half got nivolumab by drip every two weeks, with the amount calculated from body weight by the treating team. Half got everolimus, a 10 mg tablet once a day. Nobody was blinded; everyone knew which arm they were in.
Everolimus is a tablet taken at home. If you are on it, the amount on your own prescription is what to follow, not the trial figure.
The numbers
| Field | Detail |
|---|---|
| Trial | CheckMate 025 |
| Identifier | NCT01668784 |
| Phase | Phase 3 |
| Design | Randomised, open-label |
| Cancer type | Advanced clear-cell kidney cancer, previously treated |
| Comparator | Nivolumab against everolimus |
| Primary endpoint | Overall survival |
Median survival was 25.0 months with nivolumab and 19.6 months with everolimus. The hazard ratio for death was 0.73 (98.5% CI 0.57 to 0.93; p=0.002), and the trial passed the bar it had set for itself in advance.
Tumours shrank in 25% of the nivolumab group and 5% of the everolimus group (odds ratio 5.98, 95% CI 3.68 to 9.72, p<0.001).
Why progression-free survival missed it
Median time before the cancer grew was 4.6 months with nivolumab and 4.4 months with everolimus. The hazard ratio was 0.88 (95% CI 0.75 to 1.03) with a p-value of 0.11. On that measure the two drugs were the same.
Immune drugs can take a while to work, and a tumour can swell before it shrinks as immune cells move into it. A scan at a fixed date can log that as growth. Judged only on scans, nivolumab looked like a failure here. Judged on how long people actually lived, it did not.
The side-effect ledger ran the other way
Serious treatment-related side effects — grade 3 or 4 — hit 19% of the nivolumab group and 37% of the everolimus group. The commonest serious problem on nivolumab was fatigue, in 2%. On everolimus it was anaemia, in 8%.
So the drug that worked better was also the easier one to take. That is not the usual trade.
What to keep in perspective
- This was second-line treatment. Immune-based combinations are now given first for many people, so fewer reach the exact situation this trial studied, and everolimus is no longer the natural comparison.
- Only clear-cell kidney cancer was studied. Other subtypes were not.
- The trial was open-label. Knowing your assignment can shape how side effects and symptoms get reported.
- A median is a midpoint, not a forecast. Half the nivolumab group lived less than 25 months.
Questions if kidney cancer has come back
- Is my cancer clear-cell, and does that change what is on the table?
- What has already been tried, and what does that rule in or out?
- If an early scan looks worse, how will you decide whether to stop?
Sources
This article was written from the sources below, which were checked on the source-check date shown above.
How this article was prepared
Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.
Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.
Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Kidney cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.